Johnson and Johnson Rybrevant Faspro Gets USFDA Accelerated Approval for Advanced Head, Neck Cancer
Written By : sheeba farhat
Published On 2026-11-06 13:43 GMT | Update On 2026-11-06 13:43 GMT
Bengaluru: The US Food and Drug Administration on Thursday granted accelerated approval to Johnson & Johnson's treatment for patients with an advanced form of head and neck cancer whose disease has worsened after chemotherapy and immunotherapy.
The drug, Rybrevant Faspro, is approved for patients with recurrent or metastatic head and neck squamous cell carcinoma, a hard-to-treat cancer for which effective treatment options remain limited, the FDA said.
The agency said the decision was based on data from a trial of 102 patients in which 42% of those treated with the drug saw their tumors shrink or disappear.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.